Salvage Hypofractionated Radiotherapy for Biochemically Recurrent Prostate Cancer After Radical Prostatectomy

International Journal of Radiation Oncology Biology Physics

Volumn 70, Issue 2, 2008, Pages 449-455

  Wong, Gordon W ^a   Palazzi Churas, Kerrin L ^a   Jarrard, David F ^a   Paolone, David R ^a   Graf, Andrew K ^a   Hedican, Sean P ^a   Wegenke, John D ^a   Ritter, Mark A ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Biochemical recurrence; Prostate cancer; Prostatectomy; Radiotherapy; Salvage therapy

Indexed keywords

ANTIGENS; BIOCHEMISTRY; TOXICITY; TUMORS;

BIOCHEMICAL RECURRENCE; PROSTATE CANCER; SALVAGE THERAPY;

RADIOTHERAPY;

PROSTATE SPECIFIC ANTIGEN;

ACUTE TOXICITY; ADULT; AGED; ARTICLE; BIOCHEMISTRY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CHRONIC TOXICITY; CLINICAL ARTICLE; DIARRHEA; DISEASE COURSE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; MALE; PAIN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE FRACTIONATION; RECTUM HEMORRHAGE; RECURRENT CANCER; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE;

AGED; DOSE FRACTIONATION; FOLLOW-UP STUDIES; GASTROINTESTINAL TRACT; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT FAILURE; UROGENITAL SYSTEM;

EID: 38149028486     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.06.042     Document Type: Article

References (42)

1. Han M., Partin A.W., Pound C.R., et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: The 15-year Johns Hopkins experience. Urol Clin North Am 28 (2001) 555-565
2. Roehl K.A., Han M., Ramos C.G., et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results. J Urol 172 (2004) 910-914
3. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Death in patients with recurrent prostate cancer after radical prostatectomy: Prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol 25 (2007) 1765-1771
4. Anscher M.S., Clough R., and Dodge R. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: The first 10 years. Int J Radiat Oncol Biol Phys 48 (2000) 369-375
5. Catton C., Gospodarowicz M., Warde P., et al. Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother Oncol 59 (2001) 51-60
6. Hagan M., Zlotecki R., Medina C., et al. Comparison of adjuvant versus salvage radiotherapy policies for postprostatectomy radiotherapy. Int J Radiat Oncol Biol Phys 59 (2004) 329-340
7. Kalapurakal J.A., Huang C.F., Neriamparampil M.M., et al. Biochemical disease-free survival following adjuvant and salvage irradiation after radical prostatectomy. Int J Radiat Oncol Biol Phys 54 (2002) 1047-1054
8. Katz M.S., Zelefsky M.J., Venkatraman E.S., et al. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol 21 (2003) 483-489
9. Morris M.M., Dallow K.C., Zietman A.L., et al. Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 38 (1997) 731-736
10. Nudell D.M., Grossfeld G.D., Weinberg V.K., et al. Radiotherapy after radical prostatectomy: Treatment outcomes and failure patterns. Urology 54 (1999) 1049-1057
11. Song D.Y., Thompson T.L., Ramakrishnan V., et al. Salvage radiotherapy for rising or persistent PSA after radical prostatectomy. Urology 60 (2002) 281-287
12. Stephenson A.J., Scardino P.T., Kattan M.W., et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25 (2007) 2035-2041
13. Stephenson A.J., Shariat S.F., Zelefsky M.J., et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291 (2004) 1325-1332
14. Taylor N., Kelly J.F., Kuban D.A., et al. Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 56 (2003) 755-763
15. Valicenti R.K., Gomella L.G., Ismail M., et al. Effect of higher radiation dose on biochemical control after radical prostatectomy for pT3N0 prostate cancer. Int J Radiat Oncol Biol Phys 42 (1998) 501-506
16. Vicini F.A., Ziaja E.L., Kestin L.L., et al. Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. Urology 54 (1999) 111-117
17. Ward J.F., Zincke H., Bergstralh E.J., et al. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol 172 6 Pt 1 (2004) 2244-2248
18. Peeters S.T., Heemsbergen W.D., Koper P.C., et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24 (2006) 1990-1996
19. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
20. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 294 (2005) 1233-1239
21. Kupelian P.A., Thakkar V.V., Khuntia D., et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Long-term outcomes. Int J Radiat Oncol Biol Phys 63 (2005) 1463-1468
22. Higgins G.S., McLaren D.B., Kerr G.R., et al. Outcome analysis of 300 prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys 65 (2006) 982-989
23. Livsey J.E., Cowan R.A., Wylie J.P., et al. Hypofractionated conformal radiotherapy in carcinoma of the prostate: Five-year outcome analysis. Int J Radiat Oncol Biol Phys 57 (2003) 1254-1259
24. Lukka H., Hayter C., Julian J.A., et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 23 (2005) 6132-6138
25. Madsen B.L., Hsi R.A., Pham H.T., et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results. Int J Radiat Oncol Biol Phys 67 (2007) 1099-1105
26. Pollack A., Hanlon A.L., Horwitz E.M., et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 64 (2006) 518-526
27. Ritter M.A., Forman J.D., Petereit D.G., et al. Dose-per-fraction escalation for localized prostate cancer-A multi-institutional phase I/II trial. [Abstract]. Int J Radiat Oncol Biol Phys 66 Suppl. (2006) S11
28. Yeoh E.E., Holloway R.H., Fraser R.J., et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: Updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 66 (2006) 1072-1083
29. Bentzen S.M., and Ritter M.A. The alpha/beta ratio for prostate cancer: What is it, really?. Radiother Oncol 76 (2005) 1-3
30. Fowler J., Chappell R., and Ritter M. Is alpha/beta for prostate tumors really low?. Int J Radiat Oncol Biol Phys 50 (2001) 1021-1031
31. Lee L.W., McBain C.A., Swindell R., et al. Hypofractionated radiotherapy as salvage for rising prostate-specific antigen after radical prostatectomy. Clin Oncol (R Coll Radiol) 16 (2004) 517-522
32. Syndikus I., Pickles T., Kostashuk E., et al. Postoperative radiotherapy for stage pT3 carcinoma of the prostate: Improved local control. J Urol 155 (1996) 1983-1986
33. Chinnaiyan P., Tome W., Patel R., et al. 3D-ultrasound guided radiation therapy in the post-prostatectomy setting. Technol Cancer Res Treat 2 (2003) 455-458
34. Keller H., Tome W., Ritter M.A., et al. Design of adaptive treatment margins for non-negligible measurement uncertainty: Application to ultrasound-guided prostate radiation therapy. Phys Med Biol 49 (2004) 69-86
35. Schultheiss T.E., Lee W.R., Hunt M.A., et al. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 37 (1997) 3-11
36. Hanlon A.L., Schultheiss T.E., Hunt M.A., et al. Chronic rectal bleeding after high-dose conformal treatment of prostate cancer warrants modification of existing morbidity scales. Int J Radiat Oncol Biol Phys 38 (1997) 59-63
37. Valicenti R.K., Gomella L.G., Ismail M., et al. Durable efficacy of early postoperative radiation therapy for high-risk pT3N0 prostate cancer: The importance of radiation dose. Urology 52 (1998) 1034-1040
38. Bolla M., van Poppel H., Collette L., et al. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet 366 (2005) 572-578
39. Wiegel T., Bottke D., Willich N., et al. Phase III results of adjuvant radiotherapy (RT) versus "wait and see" (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP) (ARO 96-02/AUO AP 09/95). Proc Am Soc Clin Oncol 23 (2005) 4513
40. Thompson I.M.J., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial. JAMA 296 (2006) 2329-2335
41. D'Amico A.V., Kantoff P., Loffredo M., et al. Predictors of mortality after prostate-specific antigen failure. Int J Radiat Oncol Biol Phys 65 (2006) 656-660
42. D'Amico A.V., Moul J., Carroll P.R., et al. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 172 5 Pt 2 (2004) S42-S47